Clearant Completes Successful Quarter with Record Number of Tissue Implants Distributed.

Strong Surgeon Interest and Sales Momentum Mark First Full Quarter of Direct Sales Initiative

LOS ANGELES -- Clearant, Inc. (OTCBB:CLRI) today announced that a record 52 Clearant Sterile Implant[R] cervical spinal and soft tissue allografts were distributed during the third quarter of 2006, the first complete quarter since the Company began making Clearant Sterile Implants available directly to surgeons and clinics.

"Based on the positive response from our current and prospective customers, we expect the revenue from Clearant Sterile Implants to continue to increase in the fourth quarter of 2006," said Clearant Chief Executive Officer Alain Delongchamp. "Awareness and attention to sterilization is becoming more widespread within the orthopedic surgeon community and we're seeing increasing demand for Clearant Sterile Implants."

Demand for Clearant Sterile Implants continues to grow as evident by the recent groundswell of interest from spinal surgeons that visited Clearant's exhibit booth at a national meeting of spinal surgeons held last week in Seattle, WA. Numerous spinal surgeons at the program expressed a high degree of interest in potentially converting their practices to the use of Clearant Sterile Implants.

Mr. Delongchamp added, "We are very pleased with the positive response that Clearant has received from spinal surgeons with whom we met in Seattle and, more broadly, the surgeons and medical community."

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process, which substantially reduces all types of bacteria and viruses in biological products while maintaining the functionality of the underlying tissue implant or protein. The Company began to distribute directly to surgeons, hospitals and clinics Clearant Process sterile implants in June 2006; in addition, Clearant continues to license the Clearant Process and provides its patented sterilization services to tissue banks and other biological products manufacturers. As of the end of 1Q 2006, Clearant had 10 license and service agreements with tissue banks. To date more than 8,000 patients have been successfully implanted with Clearant Process sterile implants supplied by one of the Company's licensed partners. Whereas various competing sterilization methods only kill specific types of pathogens (such as bacteria or lipid-enveloped viruses) for specific products, the Clearant Process reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. Also, the Clearant Process can be applied at various stages of product processing and/or manufacturing, including in the final packaging. For more information, please visit www.clearant.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, in particular statements regarding surgeons strongly recommending the use of implants with tissue treated by the CLEARANT PROCESS, and the conclusions from a study by surgeons to build demand for sterilized tissue. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, results of additional clinical studies, acceptance and success of our direct distribution of allografts, efficacy of the technology, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC, available on the SEC web site http://www.sec.gov.